News
The Augurex team brings together leading scientific, clinical, technical and commercial expertise to ensure that our research translates into advanced diagnostics for improved patient outcomes.
AiArthritis has launched a new patient education feature focused on the 14-3-3eta blood test in rheumatoid arthritis (RA)
Vancouver, Canada – October 22, 2025 — Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that AiArthritis has launched a new patient education feature focused on the 14-3-3eta blood test in rheumatoid arthritis (RA)....
Augurex to Exhibit and Present New Data on Anti-14-3-3eta Multiplex in Axial Spondyloarthritis at ACR Convergence 2025
Vancouver, Canada – October 17, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that it will be exhibiting at Booth 919 and presenting new data at the American College of Rheumatology (ACR) Convergence 2025, taking...
Augurex Announces Expansion of Availability of the JOINTstat® Diagnostic Test for Rheumatoid Arthritis with MitogenDx
Augurex has partnered with MitogenDx to expand access to JOINTstat® testing across Canada, improving physician and patient access to advanced tools for rheumatoid arthritis (RA) diagnosis and monitoring. JOINTstat® is a Health Canada-approved Class II in vitro...
Augurex Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
Augurex to present new data from clinical studies in an oral presentation and two poster presentations at ACR Convergence 2025, taking place October 24 – 29 in Chicago, IL. Professor Raj Sengupta will present new data in on the use of autoantibodies to 14-3-3eta in...
Augurex to Exhibit and Present New Data at CCR West 2025
Vancouver, Canada – September 8, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced it will exhibit and present new data at the Congress of Clinical Rheumatology West (CCR West) 2025, taking place September 18–21 in...
Augurex to Exhibit and Sponsor Industry Lunch Seminar at the AMLI 2025 Annual Meeting
Vancouver, Canada – August 5, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced its participation in the Association of Medical Laboratory Immunologists (AMLI) 38th Annual Meeting, taking place August 14–17 at the Hyatt...
Augurex to Exhibit at ADLM 2025, July 27–31 in Chicago, Illinois
Vancouver, Canada – July 17, 2025 – Augurex Life Sciences today announced it will be exhibiting and presenting new data at ADLM 2025 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo), taking place July 27–31 in Chicago, IL. As one of the world’s...
Augurex to attend and sponsor Ten Topics in Rheumatology 2025, July 3–4 in London, UK
Augurex to attend and sponsor Ten Topics in Rheumatology 2025, July 3–4 in London, UK. Showcasing biomarker-based diagnostics: JOINTstat® for rheumatoid arthritis and SPINEstat™, a first-in-class diagnostic for axial spondyloarthritis Vancouver, Canada – June 26, 2025...
Augurex to Sponsor the AS/axSpA Back Summit 2025 Hosted by the Canadian Spondyloarthritis Association (CSA)
Augurex to sponsor the AS/axSpA Back Summit 2025, hosted by the Canadian Spondyloarthritis Association (CSA) Featuring SPINEstat™, a Health Canada-approved, first-in-class diagnostic blood test for the early and accurate detection of axial spondyloarthritis (axSpA)....
Augurex Announces Agreement with ARUP Laboratories to Expand Access to Advanced Rheumatoid Arthritis Diagnosis with the Launch of 14-3-3η (eta) Test
Augurex Life Sciences Corp. announces the launch of the 14-3-3η test by ARUP Laboratories, enhancing the early diagnosis and management of RA.The collaboration between Augurex and ARUP Laboratories highlights a mutual dedication to improving patient outcomes and...
Augurex Achieves MDSAP Certification
Vancouver, BC – August 22, 2024 – Augurex Life Sciences Corp., a leader in biomarker-driven diagnostic solutions for the detection and management of autoimmune diseases, today announced its successful certification under the Medical Device Single Audit Program...
Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEO
Augurex Life Sciences Corp. Names Healthcare Leader Neil Klompas to Succeed Co-Founder Dr. Norma Biln as President and CEO Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEO Co-Founder and outgoing CEO Dr. Norma Biln to helm research...
Life Sciences BC Names Augurex 2024 Emerging Company of the Year
VANCOUVER, BC – Life Sciences BC (LSBC) is pleased to announce the recipients of the 26th Annual Life Sciences BC Awards presented by Farris. These awards recognize the exceptional achievements of individuals, companies, and organizations across British Columbia’s...
New Day Diagnostics Collaboration
Augurex and New Day Diagnostics Collaborate to Launch SPINEstat™, Revolutionizing Early Diagnosis and Management of Ankylosing Spondylitis Vancouver, BC, Canada and Knoxville, TN, USA, 30 May 2024 – Augurex and New Day Diagnostics are excited to announce their...
Augurex has received $5M in funding from PacifiCan
Government of Canada invests almost $14 million to drive innovation and economic growth in Vancouver.Today, the Honourable Mary Ng, Minister of Export Promotion, International Trade and Economic Development on behalf of the Honourable Harjit S. Sajjan, Minister of...
Leading health publications are sharing the 14-3-3η blood test as part of the standard of care
Practical Pain Management highlights the 14-3-3η blood test The 14-3-3η blood test has been highlighted for earlier, more accurate diagnosis of rheumatoid arthritis by Practical Pain Management (PPM), a trusted publication providing evidence-based strategies for the...
14-3-3η: How Joint Involvement “Spreads”
14-3-3η: A Critical Mass of Data A recent systematic literature review describes a substantive body of evidence for 14-3-3η's clinically important role along the whole continuum of rheumatoid arthritis and autoimmune patient care.Key Statements:14-3-3η helps to assess...
10 Years of Peer-Reviewed Studies Predicting and Informing the Prognosis Profile of Autoimmune Patients
Recent journal publications are fortifying the clinically important role of the 14-3-3η blood test along the whole continuum of RA and autoimmune patient care. From RA meta-analysis data through to 14-3-3η expression in juvenile idiopathic arthritis and secondary...
Augurex to attend BIO 2025, June 16–19, in Boston, MA, the world’s largest biotechnology partnering event.
Augurex to attend BIO 2025, June 16–19, in Boston, MA, the world’s largest biotechnology partnering event. Showcasing biomarker-based diagnostics for rheumatoid arthritis and axial spondyloarthritis, including JOINTstat® and first-in-class SPINEstat™. Vancouver,...
Augurex to present a poster and share a second accepted abstract at EULAR 2025, June 11–14 in Barcelona.
Augurex to present a poster and share a second accepted abstract at EULAR 2025, taking place June 11–14 in Barcelona. New findings highlight the value of 14-3-3eta autoantibodies in improving early detection of axSpA, including in HLA-B27–negative patients. Vancouver,...
Augurex to participate in the SPARTAN 2025 Annual Meeting in Toronto, Canada
Augurex to participate in the SPARTAN 2025 Annual Meeting, taking place May 9–10 in Toronto, Canada. Featuring SPINEstat™, a Health Canada-approved, first-in-class blood test for the early diagnosis and monitoring of axial spondyloarthritis (axSpA). Vancouver, Canada...
Augurex to attend British Society for Rheumatology 2025 Annual Meeting in Manchester, UK
Augurex to attend British Society for Rheumatology 2025 Annual Meeting in Manchester, UK Highlighting biomarker-based diagnostic innovations for RA and axSpA Vancouver, Canada – April 25, 2025 – Augurex Life Sciences Corp., a leader in biomarker-based diagnostics for...
Augurex to attend CCR East 2025
Augurex to attend CCR East 2025 and present new research on 14-3-3eta auto-antibodies as a diagnostic marker for axial spondyloarthritis (axSpA). Augurex will be exhibiting at booth #66, showcasing how the 14-3-3eta test aids in the diagnosis and monitoring of...
Augurex to Present New Data at Leading Rheumatology and Diagnostics Conferences in 2025
Vancouver, Canada – April 15, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that multiple scientific abstracts have been accepted for presentation at major international rheumatology and diagnostics conferences...
Augurex attends the TRS 2025 Annual Meeting
Vancouver, Canada – February 21, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced its participation in the Tennessee Rheumatology Society (TRS) 2025 Annual Meeting taking place from February 28 – March 1 in...
Augurex attends the Canadian Rheumatology Association (CRA) 2025 Annual Scientific Meeting
Vancouver, Canada – February 19, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, is pleased to announce its participation in the Canadian Rheumatology Association (CRA) 2025 Annual Scientific Meeting, taking place February 26 –...
Augurex Attending RheumNow Live 2025
Vancouver, Canada – February 3, 2025 – Augurex is excited to announce that it will attend the RheumNow Live 2025 conference, a premier event bringing together leading rheumatologists and researchers to discuss the latest advancements in rheumatic disease diagnostics,...
Home
Products
Science
About
News
Careers
Contact


























